Drug Uses

Vaniqa (Cream) is a prescription medication applied to the skin for the reduction of unwanted facial hair in women. Vaniqa interferes with an enzyme found in the hair follicle of the skin needed for hair growth. This results in slower hair growth and improved appearance where Vaniqa is applied. Vaniqa does not permanently remove hair or "cure" unwanted facial hair. It is not a depilatory. Your treatment program should include continuation of any hair removal technique you are currently using. Vaniqa will help you manage your condition and improve your appearance.

How Taken

Apply a thin layer of Vaniqa Cream to affected areas of the face and adjacent involved areas under the chin and rub in thoroughly. Do not wash treated area for at least 4 hours. Use twice daily at least 8 hours apart or as directed by a physician. You should continue to use hair removal techniques as needed in conjunction with Vaniqa. (Vaniqa should be applied at least 5 minutes after hair removal). Cosmetics or sunscreens may be applied over treated areas after cream has dried.

Warnings/Precautions

Do not use Vaniqa if you have had an allergic reaction to it in the past. Vaniqa is in the FDA pregnancy category C. This means that it is not known whether Vaniqa will harm an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant. It is also not known whether Vaniqa passes into breast milk. Do not use Vaniqa without first talking to your doctor if you are breast-feeding a baby. Vaniqa has not been approved for use by children younger than 12 years of age.

Missed Dose

If you forget or miss a dose of Vaniqa do not try to "make it up". Return to your normal application schedule as soon as you can.

Possible Side Effects

Vaniqa may cause temporary redness, stinging, burning, tingling or rash on areas of the skin where it is applied. Hair bumps may also occur. If these persist, consult your doctor. Treatment related skin adverse events that occurred in less than 1% of the subjects treated with Vaniqa are: bleeding skin, cheilitis, and contact dermatitis, swelling of lips, herpes simplex, numbness and rosacea. Adverse events were primarily mild in intensity and generally resolved without medical treatment or discontinuation of Vaniqa.

Storage

Store at 25° C (77° F); excursions permitted to 15° C-30° C (59° F-86° F). Do not freeze. See tube crimp and carton end for expiration date and lot number.

Overdose

An overdose of Vaniqa is not likely to occur. If the cream has been ingested, or if you suspect an overdose has occurred, contact your doctor, hospital emergency room, or poison control center for advice.

More Information

Avoid getting this medication in your eyes, nose, or mouth. If this occurs, wash the area with water. If Vaniqa gets in your eyes, rinse thoroughly with water and contact your doctor.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

---

There are two leading reasons why people choose to obtain Vaniqa online. The first is cost. Due to the economics of health care in the United States, consumers often must pay a significantly higher price for medication than customers in other countries. A second reason is privacy. Some people prefer to obtain their Vaniqa online, even at a higher cost, than to consult a doctor in person about issues such as depression, hair loss, and sexual problems.


Finding Vaniqa online is not difficult; in fact, it is quite simple. Online-rxdrugs.com offers all the choices that you might possibly want. Drugs online can be harmful if you have no working knowledge of the medicine involved, but can pay off handsomely for people who are well-informed.
The main advantage of buying Vaniqa online is the reduced cost. Not only will you be able to compare and contrast the offers that are available, you will also be able to choose the ones that are available for the least amount of money. When you’ve made your choice, you don’t even have to budge: you can have your drugs online delivered right into your house, for little charge.


Q: How does the online consultation for Vaniqa work?
A: Online consultations utilizes the Internet to improve patient access to the physician. The patient no longer needs to receive a traditional physical exam by the physician. Now he simply completes an online questionnaire for Vaniqa, and this questionnaire is then submitted to the physician using our secure order system. The online consultations can never take the place of traditional medicine, they do provide a valid means for patients to receive treatment for a number of conditions that, in many circumstances, do not actually require a physical exam.


Even as Evista (raloxifene) reduced the risk of invasive breast cancer by 44%, compared with placebo, it had a significantly increased relative risk of thromboembolic events -- including fatal strokes -- according to a study of more than 10,000 postmenopausal women.
Evista was associated with a 49% increase in the relative risk of fatal stroke (P=0.05), Elizabeth Barrett-Connor, M.D., of the University of California San Diego and colleagues for the RUTH (Raloxifene Use for The Heart) trial reported in the July 13 issue of the New England Journal of Medicine.
Evista was also associated with a significant increase in risks of venous thromoboembolic events (P=0.02), but as expected Evista was associated with a significant decrease in risk of clinical vertebral fractures (P=0.007).
The 44% decrease in invasive breast cancer risk (P=0.003) among women taking Evista was driven by a highly significant reduction in estrogen-positive breast cancer (P<0.001). Evista did not reduce the risk of estrogen-negative breast cancers (P=0.40).
Women taking Evista also had significantly more hot flushes, leg cramps, and peripheral edema (P<0.001 for all compared with placebo), they wrote.
The RUTH investigators randomly assigned 10,101 postmenopausal women (mean age 67.5) with established coronary heart disease or multiple risk factors for heart disease to either 60 mg of Evista daily or placebo. The women were followed for a median of 5.6 years. The primary endpoints were coronary events and invasive breast cancer.
In this group of women at high risk for coronary events, "the difference in absolute rates of events that were decreased (i.e., breast cancer and clinical vertebral fractures) was similar to the difference in the absolute rates of events that were increased (i.e., venous thromboembolic events and fatal strokes)," the authors wrote.
And that may be the sticking point for many clinicians counseling women, said Steven Nissen, M.D., acting director of cardiology at the Cleveland Clinic.
"When a drug increases cardiovascular risk, we have to take that seriously," he said adding that Dr. Barrett-Connor and colleagues did an excellent job of "laying out the risks and benefits very clearly, with no spin."
Dr. Nissen, who was an early critic of Vioxx (rofecoxib) because of its increased risk of thromboembolic events, said that results of the RUTH trial are likely to spur debate if Lilly, the maker of Evista, seeks FDA approval for Evista for breast cancer prevention.
Currently the drug is approved for treatment and prevention of osteoporosis in postmenopausal women.
Earlier this year, results of the STAR (Study of Tamoxifen and Raloxifene) trial indicated that Evista is as effective as tamoxifen for preventing breast cancer in postmenopausal women. Tamoxifen is the only FDA approved drug for prevention of breast cancer.
Lilly said in June that it plans to ask the FDA to approve Evista for cancer prevention.
Evista and tamoxifen are both selective estrogen receptor modulators, or SERMs. SERMs were originally developed as alternatives to estrogen to treat symptoms of menopause as well as osteoporosis. But unlike estrogen, SERMs do not reduce vasomotor symptoms, although they have demonstrated efficacy in osteoporosis.
When the RUTH trial began recruiting women in 1998 it was widely believed that estrogen reduced the risk of coronary events, which led Dr. Barrett-Connor and colleagues to hypothesize that Evista would also be cardio-protective. But in 2002, investigators for the Women's Health Initiative reported that estrogen increased the risk of stroke and thromboembolic events, as well as increasing the risk of breast cancer.
The RUTH results "now allow us to say that all modulators of the estrogen receptors potentially increase the risk of cardiovascular events," said Dr. Nissen.
John T. Cole, M.D., medical director of hematology and oncology services at the Ochsner Health System in New Orleans, said that the RUTH findings coming on the heels of the STAR trial confirm that Evista has a role in chemoprevention in a select population -- but defining that population may be difficult.
Even so-called high risk women only have very small absolute risk for developing breast cancer, he said. "If you look at in terms of telling a woman that she has about a 98.4% chance of [not developing breast cancer], it is difficult to imagine her wanting chemoprevention," he said.
Nonetheless, Dr. Cole said that in both the RUTH trial and the STAR trial "as risk increased, so did the potential benefit of chemoprevention."
In an NEJM editorial, Marcia L. Stefanick, Ph.D., of the Stanford Prevention Research Center in Stanford, Calif., said the RUTH study "highlights the need to consider the risk of breast cancer as well as other risks and coexisting conditions in determining whether and when [Evista] or another SERM is warranted for an individual woman."
"For women represented by the RUTH cohort of women with or at increased risk for CHD, the moderate benefits of raloxifene for breast cancer prophylaxis do not seem to justify the risks" she wrote.
"For now," Dr. Stefanick continued, "there is no magic bullet that can reduce the risks of major health problems related to estrogens and aging without introducing other potentially serious health concerns."

Frequent Vaniqa misspellings: caniqa, baniqa, ganiqa, faniqa, vzniqa, vsniqa, vwniqa, vqniqa, vabiqa, vamiqa, vajiqa, vahiqa, vanuqa, vanjqa, vankqa, vanoqa, van9qa, van8qa, vani1a, vani2a, vaniwa, vaniaa, vaniqz, vaniqs, vaniqw, vaniqq, aniqa, vniqa, vaiqa, vanqa, vania, vaniq, avniqa, vnaiqa, vainqa, vanqia, vaniaq, vvaniqa, vaaniqa, vanniqa, vaniiqa, vaniqqa, vaniqaa

Vaniqa search phrases: Vaniqa drugstore, Vaniqa prescription, Vaniqa without prescription, Vaniqa stories, Vaniqa fedex delivery, Vaniqa pharmacy, Vaniqa generic, Vaniqa side effects, Vaniqa overnight delivery, Vaniqa purchase, Vaniqa brand name, Vaniqa rxpharmacy